Pradaxa is an anticoagulant developed by Boehringer Ingelheim used to help prevent dangerous clotting that can cause stroke or embolism. Unfortunately, it has also been reported to cause severe harm and even death in some patients.
The Gallagher Law Firm is currently investigating these reports and has collected volumes of information about Pradaxa and it’s active ingredient, dabigatran, to assist you. Call us at (713) 238-7705 if you have questions or think you have been affected by Pradaxa.
Blood Clotting & Thinning
When a cut or bruise occurs, the body sends a wave of chemicals triggering the creation of thrombin to aid in clotting the wound. This results in the platelet cells in the blood bonding together to create a clot to stop the bleeding.
In patients that suffer from arterial fibrillation, however, clotting may form within the vessels due to irregular blood flow. This unnecessary clotting may result in a pulmonary embolism or stroke. Pradaxa, a direct thrombin inhibitor, is prescribed to prevent blood clots by disallowing the thrombin from producing fibrin, a protein that causes the bond between platelets.
Because they stop the clotting process, anticoagulants such as Pradaxa can result in unnecessary bleeding. A bruise or laceration can quickly become fatal due to the lack of the body’s ability to create a clot and stifle the blood flow. Soon after the FDA’s approval of Pradaxa in 2010, reports began surfacing of patients suffering excessive bleeding after typically non-lethal incidents as a consequence of using Pradaxa.
In 2011, the FDA began investigating reports of injury or death involving serious bleeding occurring in patients taking Pradaxa after 260 reports of fatalities were said to be submitted to Boehringer Ingelheim, the manufacturer of Pradaxa and its main ingredient dabigatran etexilate.
Lawsuits involving Pradaxa have been filed against Boehringer Ingelheim for the administration of Pradaxa without providing sufficient information on how to treat a potentially fatal bleeding event with patients currently consuming dabigatran etexilate. The company appears to have failed to properly inform medical professionals and patients of the dangers involved when prescribing and using Pradaxa.
If you or someone close to you has experienced the misfortune of a serious side effect of Pradaxa, the Gallagher Law Firm is currently litigating against Boehringer Ingelheim for their lack of regard for your safety. Call us at (713) 238-7705 or contact us online to discuss your case and options.